Jeffrey Robert Ajer - 01 Jul 2026 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Director
Issuer ticker: VRDN
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 16:15:26 UTC
Prior SEC filing: 01 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Tousignant, Attorney-in-fact

Key filing fact

Jeffrey Robert Ajer filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 02 Jul 2026.

Key facts

This page summarizes Jeffrey Robert Ajer's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 16:15.

Change

Previous filing in this sequence was filed on 01 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001557533 Primary reporting owner

Ajer Jeffrey Robert

Relationship: Director
Address: C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM
Signature: /s/ Jennifer Tousignant, Attorney-in-fact
Signature date: 02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +32,341
Change %
Price: $0.000000^*
Shares after: 32,341
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,341
Exercise price: $18.48
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.